The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection

American Journal of Transplantation

Volumn 9, Issue 1, 2009, Pages 231-235

  Locke, J E ^a   Magro, C M ^b   Singer, A L ^a   Segev, D L ^a   Haas, M ^a   Hillel, A T ^a   King, K E ^a   Kraus, E ^a   Lees, L M ^a   Melancon, J K ^a   Stewart, Z A ^a   Warren, D S ^a   Zachary, A A ^a   Montgomery, R A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Antibody mediated rejection; Complement inhibitor; Desensitization; Eculizumab; Incompatible transplant; Positive crossmatch

Indexed keywords

CD20 ANTIBODY; COMPLEMENT MEMBRANE ATTACK COMPLEX; ECULIZUMAB; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADULT; ANTIBODY MEDIATED REJECTION; ARTICLE; CASE REPORT; COMPLEMENT INHIBITION; DRUG MEGADOSE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MALE; PLASMAPHERESIS; PRIORITY JOURNAL;

ADULT; ANTIBODIES, MONOCLONAL; COMPLEMENT C5; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; SALVAGE THERAPY;

EID: 58049206825     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02451.x     Document Type: Article

References (15)

1. Gloor JM, DeGoey SR, Pineda AA et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003 3 : 1017 1023.
2. Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: A single center's perspective. Pediatr Transplant 2004 8 : 535 542.
3. Kaplan B, Gangemi A, Thielke J, Oberholzer J, Sankary H, Benedetti E. Successful rescue of refractory, severe antibody mediated rejection with splenectomy. Transplantation 2007 83 : 99 100.
4. Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004 4 : 996 1001.
5. Sonnenday CJ, Warren DS, Cooper M et al. Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant 2004 4 : 1315 1322.
6. Locke JE, Zachary AA, Haas M et al. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 2007 7 : 842 846.
7. Alexander JW, First MR, Majeski JA et al. The late adverse effect of splenectomy on patient survival following cadaveric renal transplantation. Transplantation 1984 37 : 467 470.
8. Kawase T, Abe M, Ishii T et al. Short-term results in ABO-incompatible living related kidney transplantation. Transplant Proc 2002 34 : 2773.
9. Hillmen P, Young NS, Schubert J et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006 355 : 1233 1243.
10. Cooper NR. The classical complement pathway: Activation and regulation of the first complement component. Adv Immunol 1985 37 : 151 216.
11. Perkins SJ, Nealis AS. The quaternary structure in solution of human complement subcomponent C1r2C1s2. Biochem J 1989 263 : 463 469.
12. Vasil KE, Magro CM. Cutaneous vascular deposition of C5b-9 and its role as a diagnostic adjunct in the setting of diabetes mellitus and porphyria cutanea tarda. J Am Acad Dermatol 2007 56 : 96 104.
13. Watanabe J, Scornik JC. IVIG and HLA antibodies. Evidence for inhibition of complement activation but not for anti-idiotypic activity. Am J Transplant 2005 5 : 2786 2790.
14. Vo AA, Lukovsky M, Toyoda M et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med 2008 359 : 242 251.
15. Brodsky RA, Young NS, Antonioli E et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood 2008 111 : 1840 1847.